Top Biotech Company

The client was preparing to launch a novel 5-HT3 anti-emetic into the chemotherapy-induced nausea and vomiting (CINV) market in the US, EU5 and Japan, and needed to know the size of the available patient population and the likelihood of use of its new product.

Our Solution

• GlobalData used a chart audit process to identify the standard of care for chemotherapy treatment.
• The emetogenic potential of chemotherapy agents was analyzed to determine the risk of emesis of chemotherapy regimens for key tumor types, and the current use of anti-emetic agents for key chemotherapy regimens.

Outcome

Based on insights gathered through secondary and primary research, GlobalData identified the probable market size for the client’s product and recommended clinical and commercial steps to optimize uptake.